Yonglian ZHANG - Kenilworth NJ, US Amjad ALI - Kenilworth NJ, US Jared CUMMING - Winchester MA, US Duane DEMONG - Boston MA, US Qiaolin DENG - Kenilworth NJ, US Thomas H. GRAHAM - Boston MA, US Elisabeth HENNESSY - Boston MA, US Matthew A. LARSEN - Boston MA, US Kun LIU - Boston MA, US Ping LIU - Boston MA, US Umar Faruk MANSOOR - Boston MA, US Jianping PAN - Kenilworth NJ, US Christopher W. PLUMMER - Kenilworth NJ, US Aaron SATHER - Boston MA, US Uma SWAMINATHAN - Boston MA, US Huijun WANG - Westfield NJ, US - Rahway NJ, US
In its many embodiments, the present invention provides certain 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives of Formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A, R1, R2, and R4 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutic agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2and/or A2receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2receptor and/or the adenosine A2receptor.
N-Heteroaryl Indazole Derivatives As Lrrk2 Inhibitors, Pharmaceutical Compositions, And Uses Thereof
- Rahway NJ, US William P. KAPLAN - Boston MA, US Michael J. ARDOLINO - Arlington MA, US Joanna L. CHEN - Braintree MA, US Peter H. FULLER - Ashland MA, US Hakan GUNAYDIN - Somerville MA, US Derun LI - Roxbury MA, US Ping LIU - Westfield NJ, US Kaitlyn Marie LOGAN - Boston MA, US Joey METHOT - Westwood MA, US Gregori J. MORRIELLO - Randolph NJ, US Santhosh F. NEELAMKAVIL - Edison NJ, US Luis TORRES - Norwood MA, US Xin YAN - Newton MA, US Hua ZHOU - Acton MA, US
The present invention is directed to substituted certain N-heteroaryl indazole derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, R, X, Y, and Z are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.
2014 to 2000 Principal Statistician3M Pharmaceuticals, Inc
May 2005 to Feb 2012 Statistician/lead statistician on severalUS and Europe
Aug 2000 to Apr 2005 Lead statistician in Actinic Keratosis projectUniversity of Minnesota
Sep 1998 to Jun 2000 Consultant
Education:
The University of Texas 2007 to 2012 Ph.D in BiostatisticsUniversity of Minnesota 1998 to 2000 M.S in BiostatisticsFudan University 1992 to 1997 B.S in Genetics & Genetic EngineeringFudan University
Dr. Liu graduated from the Tongji Med Univ, Wuhan City, Hubei, China in 1992. She works in Newton, NJ and specializes in Internal Medicine. Dr. Liu is affiliated with Overlook Medical Center.